Based on data submitted up until and including 4 November 2026.

Epidemiological summary

Since the beginning of 2026 and as at 4 November 2026, two countries in Europe have reported locally acquired1 cases of chikungunya virus disease: France (207 cases) and Italy (1 case).

Since last week’s update, France has reported three new locally acquired chikungunya virus disease cases, bringing the total to 207 cases. These cases are distributed across 30 clusters2, with one new cluster identified in the Drôme department. Sixteen clusters are currently active, including the largest two clusters in Prayssac (36 cases), Lot department, and Cavalaire-Sur-Mer (32 cases), in Var department, and four clusters have been closed since last week.

No new locally acquired chikungunya virus disease cases have been reported by Italy since last week’s update. To date, Italy has reported one locally acquired chikungunya virus disease case in Rome. The associated cluster is closed.

In addition, on 4 November, Swiss authorities and media reported that four locally acquired cases of chikungunya in the Piana di Magadino area of Ticino, Switzerland were confirmed. These are the first locally acquired chikungunya cases ever reported in the country. As Switzerland is not reporting data to ECDC, these cases are not included in the map and table below.

Please find the current chikungunya virus disease risk assessment for mainland EU/EEA on ECDC’s dedicated chikungunya webpage.

Introduction

Chikungunya is a mosquito-borne viral disease that is emerging in Europe, with locally acquired cases reported in several EU/EEA countries. In the light of this development, the European Centre for Disease Prevention and Control has implemented seasonal enhanced surveillance to monitor the occurrence of cases in the EU/EEA. The primary objective is to inform public health authorities and support the implementation of appropriate response measures.
Chikungunya virus disease is a notifiable disease at the EU level and cases are reported in accordance with the EU case definition. The table and map in this report show the countries and areas where chikungunya virus disease cases – and their corresponding case numbers – are reported to the European surveillance portal for infectious diseases (EpiPulse Cases). In most instances, the first case reported in a cluster should be confirmed in accordance with the EU case definition. In specific situations, and at the discretion of the reporting country, a probable case may be used to designate a new cluster when confirmation is not available within a reasonable timeframe.
Please note that cases acquired in Portuguese and Spanish Outermost Regions are included. However, due to the distinct epidemiological situation and differences in surveillance systems, cases acquired in the French Outermost Regions are not included.
Here we present the report as at 4 November 2026.

Overview of chikungunya virus disease cases in the EU/EEA

Countries and regions with locally acquired chikungunya virus disease cases in 2026 as at 4 November 2026

*Nomenclature of territorial units for statistics

**Local administrative unit

When importing case_summary.csv in MS Excel, please do not forget to select Unicode (UTF-8) as encoding.

Case summary (.csv)

Spatial distribution of locally acquired chikungunya virus disease cases in 2026 as at 4 November 2026

Please follow the link to open the interactive dashboard.


  1. Cases acquired within the reporting country. ↩︎
  2. Clusters are epidemiologically- and/or microbiologically-linked cases as defined by national authorities. Clusters can also be single, sporadic cases. In most instances, reporting to ECDC is initiated only after a confirmed case is identified in a cluster. In specific situations, and at the discretion of the reporting country, a probable case may be used to designate a new cluster when confirmation is not available within a reasonable timeframe; probable cases are subsequently included once a cluster is reported. Clusters are reported as “closed”, 45 days after the last reported date of symptom onset (or any other relevant date when the date of onset is missing). This 45-day period accounts for the estimated time from symptom onset until viraemia levels are sufficient to infect a mosquito (four days), the lifespan of an Aedes mosquito in natural circumstances (23 days) and the maximum intrinsic incubation period (14 days), with an added four-day safety margin for clinical diagnosis of new cases. ↩︎